Psoriatic arthritis (moderate to severe) - adalimumab

Adalimumab should be offered as an option for treating adults with active and progressive psoriatic arthritis when: the person has arthritis with three or more tender joints and three or more swollen joints, and at least two other disease-modifying anti-rheumatic drugs (DMARDs), given on their ...

Read the complete summary

Adalimumab should be offered as an option for treating adults with active and progressive psoriatic arthritis when:

• the person has arthritis with three or more tender joints and three or more swollen joints, and
• at least two other disease-modifying anti-rheumatic drugs (DMARDs), given on their own or together, haven’t worked.

Treatment with adalimumab should be started and supervised by a specialist physician who is experienced in diagnosing and treating psoriatic arthritis.

If the person’s psoriatic arthritis has not shown a measured response at 12 weeks, their treatment with adalimumab should be stopped.

hide